You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

MSD SUB MERCK Company Profile

✉ Email this page to a colleague

« Back to Dashboard

Summary for MSD SUB MERCK
International Patents:549
US Patents:20

Drugs and US Patents for MSD SUB MERCK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 AP RX Yes No ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes 8,093,295 ⤷  Sign Up Y ⤷  Sign Up
Msd Sub Merck JANUMET XR metformin hydrochloride; sitagliptin phosphate TABLET, EXTENDED RELEASE;ORAL 202270-001 Feb 2, 2012 RX Yes No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MSD SUB MERCK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Msd Sub Merck JANUMET metformin hydrochloride; sitagliptin phosphate TABLET;ORAL 022044-002 Mar 30, 2007 6,303,661 ⤷  Sign Up
Msd Sub Merck TRUSOPT dorzolamide hydrochloride SOLUTION/DROPS;OPHTHALMIC 020408-001 Dec 9, 1994 4,797,413*PED ⤷  Sign Up
Msd Sub Merck ISENTRESS raltegravir potassium POWDER;ORAL 205786-001 Dec 20, 2013 7,217,713*PED ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for MSD SUB MERCK drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 2008-09-30
➤ Subscribe Injection 0.75 mg/mL, 100 mL vial ➤ Subscribe 2009-06-05
➤ Subscribe Tablets 400 mg ➤ Subscribe 2011-10-12
➤ Subscribe Extended-release Capsules 50 mg/500 mg and 50 mg/1000 mg ➤ Subscribe 2012-03-16
➤ Subscribe Tablets 50 mg/500 mg and 50 mg/1000 mg ➤ Subscribe 2010-10-18
➤ Subscribe Injection 2 mg/mL, 100 mL vial ➤ Subscribe 2008-12-18
➤ Subscribe Injection 1 g/vial ➤ Subscribe 2013-06-20
➤ Subscribe Ophthalmic Solution 2% ➤ Subscribe 2005-10-11
➤ Subscribe Extended-release Tablets 100 mg/1000 mg ➤ Subscribe 2012-10-22

Supplementary Protection Certificates for MSD SUB MERCK Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1441735 20221021 Netherlands ⤷  Sign Up 20221021, EXPIRES: 20221219
1412357 77 5006-2008 Slovakia ⤷  Sign Up PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
2310095 C20160051 00215 Estonia ⤷  Sign Up PRODUCT NAME: GRASOPREVIIR;REG NO/DATE: EU/1/16/1119 26.07.2016
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.